Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000
Buy Report

Published: October 31, 2022 Report Code: GDGMDHC22376IDB-ST

Select Item

Acute Lymphocytic Leukemia Pipeline Drugs Market Report Overview

Acute lymphocytic leukemia (ALL) is a cancer of the white blood cells due to the production of a large number of immature lymphocytes thus blocking the production of normal blood cells. Risk factors for ALL include exposure to radiation or chemicals, age, virus infections, and genetic factors. Symptoms include anemia, frequent infections, easy bruising, bone pain, and breathing problems. Treatment includes chemotherapy, transfusions, transplant, and medications.

The ALL pipeline drugs market research report provides comprehensive information on the therapeutics under development for ALL, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for ALL and features dormant and discontinued projects.

ALL Pipeline Drugs Market Segmentation by Targets

Some of the targets of the ALL pipeline drugs market are Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing B Cell Receptor CD22, Cells Expressing T Cell Antigen CD7, Asparagine, Bcr-Abl Tyrosine Kinase, and others.

ALL Pipeline Drugs Market Analysis, by Targets

ALL Pipeline Drugs Market Analysis, by Targets

For more ALL pipeline drugs market target insights, download a free report sample

ALL Pipeline Drugs Market Segmentation by Mechanisms of Action

Some of the key mechanisms of action of the ALL pipeline drugs market are Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Cytotoxic To Cells Expressing B Cell Receptor CD22, Cytotoxic To Cells Expressing T Cell Antigen CD7, Bcr-Abl Tyrosine Kinase Inhibitor, Asparagine Depletor, and others.

ALL Pipeline Drugs Market Analysis, by Mechanisms of Action

ALL Pipeline Drugs Market Analysis, by Mechanisms of ActionFor more mechanisms of action insights into the ALL pipeline drugs market, download a free report sample

ALL Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the ALL pipeline drugs market are intravenous, parenteral, oral, subcutaneous, intratumor, and others.

ALL Pipeline Drugs Market Analysis, by Routes of Administration

ALL Pipeline Drugs Market Analysis, by Routes of Administration

For more routes of administration insights into the ALL pipeline drugs market, download a free report sample

ALL Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the ALL pipeline drugs market are Gene-Modified Cell Therapy, Small Molecule, Monoclonal Antibody, Cell Therapy, Monoclonal Antibody Conjugated, and others.

ALL Pipeline Drugs Market Analysis, by Molecule Types

ALL Pipeline Drugs Market Analysis, by Molecule TypesFor more molecule type insights into the ALL pipeline drugs market, download a free report sample

ALL Pipeline Drugs Market - Competitive Landscape

Some of the key companies in the ALL pipeline drugs market are Novartis AG, Gracell Biotechnologies Inc, Pfizer Inc, Bristol-Myers Squibb Co, Hebei Senlang Biotechnology Co Ltd, PersonGen BioTherapeutics (Suzhou) Co Ltd, and others.

ALL Pipeline Drugs Market Analysis, by Companies

ALL Pipeline Drugs Market Analysis, by CompaniesTo know more about the ALL pipeline drugs market companies, download a free report sample

ALL Pipeline Drugs Market Report Overview

Key Targets Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing B Cell Receptor CD22, Cells Expressing T Cell Antigen CD7, Asparagine, Bcr-Abl Tyrosine Kinase, and Others
Key Mechanisms of Action Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Cytotoxic To Cells Expressing B Cell Receptor CD22, Cytotoxic To Cells Expressing T Cell Antigen CD7, Bcr-Abl Tyrosine Kinase Inhibitor, Asparagine Depletor, and Others
Key Routes of Administration Intravenous, Parenteral, Oral, Subcutaneous, Intratumor, and Others
Key Molecule Types Gene-Modified Cell Therapy, Small Molecule, Monoclonal Antibody, Cell Therapy, Monoclonal Antibody Conjugated, and Others
Key Companies Novartis AG, Gracell Biotechnologies Inc, Pfizer Inc, Bristol-Myers Squibb Co, Hebei Senlang Biotechnology Co Ltd, PersonGen BioTherapeutics (Suzhou) Co Ltd, and Others

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of ALL.
  • The pipeline guide reviews pipeline therapeutics for ALL by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in ALL therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates ALL therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for ALL

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for ALL.

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding the ALL pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.

AbbVie Inc
Abclon Inc
Achelois Cell Therapy
Actinium Pharmaceuticals Inc
Actinobac Biomed Inc
ADC Therapeutics SA
Adienne Pharma & Biotech SA
Adlai Nortye Biopharma Co Ltd
Agastiya Biotech LLC
AIkido Pharma Inc
Aileron Therapeutics Inc
AIMM Therapeutics BV (Inactive)
Alaunos Therapeutics Inc
Allterum Therapeutics LLC
Amgen Inc
Angiocrine Bioscience Inc
Apexian Pharmaceuticals Inc
Arch Oncology Inc
Armaceutica Inc
Ascentage Pharma Group International
Ascentawits Pharmaceuticals Ltd
AstraZeneca Plc
Athenex Inc
Autolus Therapeutics Plc
Avalon GloboCare Corp
AvenCell Europe GmbH
AVM Biotechnology LLC
Ayala Pharmaceuticals Inc
Bayer AG
Beijing Immunochina Pharmaceuticals Co Ltd
Bellicum Pharmaceuticals Inc
Bio-Cancer Treatment International Ltd
Bio-Path Holdings Inc
Bioceltech Therapeutics Ltd
Biocure Technology Inc
Biohaven Pharmaceutical Holding Company Ltd
Biomea Fusion Inc
BlueSphere Bio Inc
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Cambridge Innovation Technologies Consulting Ltd
Caribou Biosciences Inc
CARsgen Therapeutics Ltd
Cellectis SA
Cellestia Biotech AG
Cellular Biomedicine Group Inc
Celularity Inc
Centrymed Pharmaceutical Inc
Century Therapeutics Inc
Ceptur Therapeutics Inc
Changzhou Qianhong Bio-Pharma Co Ltd
Cheetah Cell Therapeutics Co Ltd
Chengdu USino Technology Biology Co Ltd
Chengdu Zenitar Biomedical Technology Co Ltd
Chimagen Biosciences Ltd
Chimeric Therapeutics Ltd
Chimerix Inc
China Immunotech (Beijing) Biotechnology Co Ltd
China Immunotech Co Ltd
Chongqing Precision Biotech Co Ltd
CoImmune Inc
ConverGene LLC
CRISPR Therapeutics AG
CSPC Pharmaceutical Group Ltd
Cullinan Oncology Inc
Curon Biopharmaceutical Ltd
Cyclacel Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
DEKK-TEC Inc
Delta-Fly Pharma Inc
DevaCell Inc
Diatheva srl
Diazon Pharmaceuticals Inc
DiNonA Inc
EdiGene Inc
Elf Zone Inc
Enzyme by Design Inc
Epizyme Inc
ERYTECH Pharma SA
Eureka Therapeutics Inc
Eutilex Co Ltd
ExCellThera Inc
Excelmab Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Felicitex Therapeutics Inc
Fochon Pharmaceutical Ltd
Fusion Pharmaceuticals US Inc
Gamida Cell Ltd
Generium
Gilead Sciences Inc
Gracell Biotechnologies Inc
Guangzhou Bio-gene Technology Co Ltd
Hangzhou Minsheng Pharmaceutical Group Co Ltd
Hangzhou Qihan Biotechnology Co Ltd
Hebei Senlang Biotechnology Co Ltd
HemoGenyx Pharmaceuticals Plc
Henan Honghui Biotechnology Co Ltd
HighPass Bio Inc
Hillstream BioPharma Inc
HK inno.N Corp
Housey Pharmaceutical Research Laboratories LLC
HRAIN Biotechnology Co Ltd
Humanigen Inc
Hunan Siweikang Therapeutics Ltd
iCell Gene Therapeutics LLC
iDD biotech SAS
IGM Biosciences Inc
Iksuda Therapeutics Ltd
ImCheck Therapeutics SAS
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
ImmunityBio Inc
ImmunoAct Pvt Ltd
ImmunoGen Inc
Immunotech Biopharm Ltd
IN8bio Inc
Inatherys
Incyte Corp
Innate Pharma SA
InnoBation Bio
InnoCare Pharma Ltd
Interprotein Corp
Jazz Pharmaceuticals Plc
Jiangxi Shanxing Biotechnology Co Ltd
Johnson & Johnson
Juventas Cell Therapy Ltd
Karyopharm Therapeutics Inc
Kecellitics Biotech Co Ltd
Kenjockety Biotechnology Inc
Kiromic BioPharma Inc
Kronos Bio Inc
Kymera Therapeutics Inc
Legend Biotech Corp
LegoChem Biosciences Inc
Les Laboratoires Servier SAS
Light Chain Bioscience
Lin Bioscience Inc
Luminary Therapeutics Inc
MAA Laboratories Inc
MacroGenics Inc
Mana Therapeutics Inc
MannKind Corp
ManysmarT Therapeutics Inc
Marker Therapeutics Inc
medac GmbH
MediSix Therapeutics Pte Ltd
MedPacto Inc
Merck & Co Inc
Meryx Inc
Millennium Pharmaceuticals Inc
Miltenyi Biomedicine GmbH
Mito BioPharm LLC
Molecular Templates Inc
Nabriva Therapeutics Plc
Nanjing Bioheng Biotech Co Ltd
Nanjing CART Medical Technology Co Ltd
Nanjing Iaso Biotherapeutics Co Ltd
Nanjing KAEDI Biotech Inc
Nanocopoeia LLC
NanoValent Pharmaceuticals Inc
Nektar Therapeutics
Newave Pharmaceutical Inc
Nkarta Inc
Nohla Therapeutics Inc
Novartis AG
NovoMedix LLC
Omeros Corp
Onconova Therapeutics Inc
OncoSynergy Inc
OncoTartis Inc
OneChain Immunotherapeutics
Orca Biosystems Inc
Orgenesis Inc
Oxcia AB
Pascal Biosciences Inc
PentixaPharm GmbH
PeproMene Bio Inc
PersonGen BioTherapeutics (Suzhou) Co Ltd
Pfizer Inc
Pharma Mar SA
PharmaEssentia Corp
Pinotbio Inc
Porton Biopharma Ltd
PPD Australia Pty Ltd
Precigen Inc
Precision Biosciences Inc
Provectus Biopharmaceuticals Inc
PTC Therapeutics Inc
Regenacy Pharmaceuticals LLC
Regeneron Pharmaceuticals Inc
ReguGene Co Ltd
Retrotherapy LLC
Ryvu Therapeutics SA
Sabz Biomedicals
Sana Biotechnology Inc
Sanofi
Sareum Holdings Plc
SciTech Development LLC
SELLAS Life Sciences Group Inc
Shandong New Time Pharmaceutical Co Ltd
Shanghai Biomed-Union Biotechnology Co Ltd
Shanghai Bioray Laboratory Inc
Shanghai GeneChem Co Ltd
Shanghai Keqi Pharmaceutical Technology Co Ltd
Shanghai Longyao Biotechnology Co Ltd
Shanghai Pharmaceuticals Holding Co Ltd
Shanghai Simnova Biotechnology Co Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Shanghai YaKe Biotechnology Co Ltd
Shenzhen BinDeBio Ltd
Shorla Pharma Ltd
SinoCelltech Group Ltd
Smart Immune SAS
Sorrento Therapeutics Inc
SpecificiT Pharma Inc
Sumitomo Pharma Co Ltd
Sun Pharma Advanced Research Company Ltd
Sunnycell Therapeutics Ltd
SunRock Biopharma SL
Suzhou Fundamenta Therapeutics Co Ltd
Synaptogenix Inc
Syncopation Life Sciences Inc
Syndax Pharmaceuticals Inc
SYNIMMUNE GmbH
Systimmune Inc
Tacitus Therapeutics Inc
Takara Bio Inc
Takeda Pharmaceutical Co Ltd
TC BioPharm Ltd
TCR2 Therapeutics Inc
Telix Pharmaceuticals Ltd
Tianjin Mycure Medical Technology Co Ltd
Tianweiyuan and Biomedicine Shanghai Co Ltd
TotalClarity Inc
Triphase Accelerator Corp
TScan Therapeutics Inc
UWELL Biopharma Inc
Vincerx Pharma Inc
VioQuest Pharmaceuticals Inc (Inactive)
Wellington Zhaotai Therapies Ltd
Wugen Inc
Wuhan Bio-Raid Biotechnology Co Ltd
Wyze Biotech Co Ltd
Xbrane Biopharma AB
Xencor Inc
Xi'An Yufan Biotechnology Co Ltd
Xiamen Nuokang Biotechnology Co Ltd
Xspray Pharma AB
Zhejiang Teruisi Pharmaceutical Co Ltd
Zhuobo Yong Ji (Shanghai) Biological Pharmaceutical Co Ltd
Zovis Pharmaceuticals

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Overview

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Companies Involved in Therapeutics Development

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Drug Profiles

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Dormant Projects

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Discontinued Products

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Dormant Projects, 2022

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Oncology reports
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Pharmaceuticals
New
Clinical Trials Scorecard for Investigations in 2023
$695 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more